Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Colorcon
Harvard Business School
Moodys
Dow

Last Updated: May 26, 2022

Teva Parenteral Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for TEVA PARENTERAL, and what generic and branded alternatives to TEVA PARENTERAL drugs are available?

TEVA PARENTERAL has forty-seven approved drugs.



Summary for Teva Parenteral
US Patents:0
Tradenames:39
Ingredients:37
NDAs:47
Patent Litigation for Teva Parenteral: See patent lawsuits for Teva Parenteral

Drugs and US Patents for Teva Parenteral

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Parenteral DOBUTAMINE HYDROCHLORIDE dobutamine hydrochloride INJECTABLE;INJECTION 074206-001 Oct 19, 1993 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Parenteral CLINDAMYCIN PHOSPHATE clindamycin phosphate INJECTABLE;INJECTION 063282-001 May 29, 1992 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Parenteral DEXAMETHASONE SODIUM PHOSPHATE dexamethasone sodium phosphate INJECTABLE;INJECTION 081126-001 Aug 31, 1990 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Parenteral ADRUCIL fluorouracil INJECTABLE;INJECTION 040023-001 Oct 18, 1991 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Parenteral CYTARABINE cytarabine INJECTABLE;INJECTION 016793-001 Approved Prior to Jan 1, 1982 DISCN Yes No See Plans and Pricing See Plans and Pricing
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-002 Apr 29, 1993 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Parenteral CLINDAMYCIN PHOSPHATE clindamycin phosphate INJECTABLE;INJECTION 063041-001 Dec 29, 1989 DISCN No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Teva Parenteral

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Parenteral CYTARABINE cytarabine INJECTABLE;INJECTION 016793-001 Approved Prior to Jan 1, 1982 3,444,294 See Plans and Pricing
Teva Parenteral CYTARABINE cytarabine INJECTABLE;INJECTION 016793-002 Approved Prior to Jan 1, 1982 3,444,294 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Medtronic
Boehringer Ingelheim
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.